FDA Designates MM120 (LSD) Breakthrough Therapy for Generalized Anxiety Disorder
Link: businesswire.com/news/home/202…
Discussion: news.ycombinator.com/item?id=3…
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing nwww.businesswire.com
lebochequirit
in reply to Arte Plus 7 (inoffiziell) • • •Kinder, die sich die Augen zuhalten. Danke für nichts, Dokufilmer. Deine Story hätte auch ohne sowas funktioniert.